Shares of Organovo Holdings, Inc. (NASDAQ:ONVO) have been given a consensus broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and two have issued a strong buy rating on the company. Organovo Holdings’ rating score has declined by 25.6% in the last 90 days as a result of various analysts’ upgrades and downgrades.
Brokers have set a twelve-month consensus price target of $3.25 for the company and are predicting that the company will post ($0.10) earnings per share for the current quarter, according to Zacks. Zacks has also given Organovo Holdings an industry rank of 109 out of 265 based on the ratings given to related companies.
Several research firms have recently issued reports on ONVO. Jefferies Group LLC reaffirmed a “buy” rating and set a $4.00 price target on shares of Organovo Holdings in a research note on Thursday, July 27th. ValuEngine downgraded Organovo Holdings from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Zacks Investment Research raised Organovo Holdings from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research note on Wednesday, October 11th. Raymond James Financial, Inc. downgraded shares of Organovo Holdings from an “outperform” rating to a “market perform” rating and set a $5.00 target price for the company. in a research note on Friday, November 10th. Finally, Citigroup Inc. downgraded shares of Organovo Holdings to a “market perform” rating in a research note on Friday, November 10th.
Organovo Holdings (NASDAQ:ONVO) traded up $0.01 during trading hours on Friday, hitting $1.52. The stock had a trading volume of 535,725 shares, compared to its average volume of 1,066,379. Organovo Holdings has a fifty-two week low of $1.32 and a fifty-two week high of $4.08.
Organovo Holdings (NASDAQ:ONVO) last released its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. The business had revenue of $1.36 million during the quarter, compared to the consensus estimate of $1.38 million. Organovo Holdings had a negative return on equity of 65.63% and a negative net margin of 923.89%. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. research analysts forecast that Organovo Holdings will post -0.36 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Organovo Holdings by 8.5% in the 1st quarter. Vanguard Group Inc. now owns 4,250,017 shares of the medical research company’s stock valued at $13,515,000 after buying an additional 333,034 shares during the period. Ark Investment Management LLC grew its holdings in Organovo Holdings by 134.5% in the 2nd quarter. Ark Investment Management LLC now owns 1,445,039 shares of the medical research company’s stock valued at $3,800,000 after buying an additional 828,787 shares during the period. Metropolitan Life Insurance Co. NY grew its holdings in Organovo Holdings by 15.0% in the 1st quarter. Metropolitan Life Insurance Co. NY now owns 68,487 shares of the medical research company’s stock valued at $218,000 after buying an additional 8,958 shares during the period. Essex Investment Management Co. LLC grew its holdings in Organovo Holdings by 27.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 458,774 shares of the medical research company’s stock valued at $1,018,000 after buying an additional 98,417 shares during the period. Finally, Teachers Advisors LLC grew its holdings in Organovo Holdings by 40.9% in the 2nd quarter. Teachers Advisors LLC now owns 235,489 shares of the medical research company’s stock valued at $619,000 after buying an additional 68,412 shares during the period. 26.84% of the stock is owned by hedge funds and other institutional investors.
WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/10/organovo-holdings-inc-onvo-given-average-recommendation-of-buy-by-brokerages.html.
About Organovo Holdings
Get a free copy of the Zacks research report on Organovo Holdings (ONVO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Organovo Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.